Zentalis, On Sunday, Announced Interim DENALI Part 1b Data Showing Median Overall Survival Of 15.8 Months With Azenosertib Monotherapy In Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
Share
Why It Matters
Zentalis tested a new cancer medicine in sick patients. The results showed patients lived longer than expected with this treatment.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.